Neisseria gonorrhoeae

(Redirected from Gonococcal)

Background

Clinical Features

Differential Diagnosis

Sexually transmitted diseases


Vesiculobullous rashes

Febrile

Afebrile

Evaluation

Workup

  • Dependent upon the infected organ
  • PCR or culture on Thayer-Martin agar (most common)

Management

Presumed GC/chlamydia of cervix, urethra, or rectum (uncomplicated)[1]

Typically, treatment for both gonorrhea and chlamydia is indicated, if one entity is suspected.

Standard


Ceftriaxone contraindicated

^Additional chlamydia coverage only needed if treated with cefixime only

Partner Treatment

Presumed GC/chlamydia of the pharynx (uncomplicated)[2]

Standard
Typically, treatment for both gonorrhea and chlamydia is indicated, if one entity is suspected.

  • Gonorrhea
    • Ceftriaxone IM x 1
      • 500 mg, if weight <150 kg
      • 1 g, if weight ≥150 kg
  • Chlamydia


Ceftriaxone contraindicated

  • No reliable alternative treatments are available for pharyngeal gonorrhea
    • For persons with a history of a beta-lactam allergy, a thorough assessment of the reaction is recommended.[3]
    • For persons with an anaphylactic or other severe reaction (e.g. Stevens Johnson syndrome) to ceftriaxone, consult an infectious disease specialist for an alternative treatment recommendation.


Test of Cure
CDC recommends a repeat culture be obtained 7-14 days after initial treatment only in persons with pharyngeal gonorrhea.

Specific Disease Processes


Antibiotic Dosing

Adult

Pediatric

Antibiotic Sensitivities[4]

Category Antibiotic N. gonorrhoeae
Penicillins Penicillin G 0
Penicillin V 0
Anti-Staphylocccal Penicillins Methicillin 0
Nafcillin/Oxacillin 0
Dicloxacillin 0
Amino-Penicillins AMP/Amox 0
Amox-Clav +
AMP-Sulb +
Anti-Pseudomonal Penicillins Ticar-Clav +
Pip-Tazo +
Carbapenems Doripenem +
Ertapenem +
Imipenem +
Meropenem +
Aztreonam +
Fluroquinolones Ciprofloxacin +*
Ofloxacin +*
Levofloxacin +*
Moxifloxacin +*
Gemifloxacin
Gatifloxacin +*
1st G Cephalo Cefazolin +
2nd G Cephalo Cefotetan +/-
Cefoxitin +/-
Cefuroxime +/-
3rd/4th G Cephalo Cefotaxime +/-
Cefizoxime +/-
CefTRIAXone +
Ceftaroline +
CefTAZidime +/-
Cefepime +
Oral 1st G Cephalo Cefadroxil 0
Cephalexin 0
Oral 2nd G Cephalo Cefaclor +/-
Cefproxil +/-
Cefuroxime +/-
Oral 3rd G Cephalo Cefixime +
Ceftibuten +/-
Cefpodox/ Cefdinir/ Cefditoren +
Aminoglycosides Gentamicin 0
Tobramycin 0
Amikacin 0
Chloramphenicol +
Clindamycin 0
Macrolides Erythromycin +/-
Azithromycin +/-
Clarithromycin +/-
Ketolide Telithromycin +
Tetracyclines Doxycycline +/-
Minocycline +/-
Glycylcycline Tigecycline +
Sulfonamides TMP-SMX +/-
Urinary Agents Nitrofurantoin +
Fosfomycin +
Other Rifampin +
Metronidazole 0
Quinupristin-dalfoppristin +
Linezolid
Daptomycin 0
Colistimethate 0
Telavancin 0
Vancomycin 0

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

Table Overview

References

  1. Cyr SS et al. Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. MMWR. Center for Disease Control and Prevention. 2020. 69(50):1911-1916
  2. Cyr SS et al. Update to CDC’s Treatment Guidelines for Gonococcal Infection, 2020. MMWR. Center for Disease Control and Prevention. 2020. 69(50):1911-1916
  3. CDC. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2015;64(No. RR-3). https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm.
  4. Sanford Guide to Antimicrobial Therapy 2010

Disposition

  • Depends on clinical features/presentation

See Also

References